Trials / Completed
CompletedNCT02217826
Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Aspireo Pharmaceuticals Limited · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
In this single-dose, randomized, 5-way cross-over study, healthy volunteers were treated with the highest approved dose of octreotide, three different doses of Somatoprim (DG3173) and placebo control. The main purpose of the study was to investigate the effects of each treatment on the control of plasma glucose as well as the secretion of insulin and glucagon following a standard meal.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DG3173 | |
| DRUG | Saline | |
| DRUG | Octreotide |
Timeline
- Primary completion
- 2014-04-01
- First posted
- 2014-08-15
- Last updated
- 2014-08-19
Source: ClinicalTrials.gov record NCT02217826. Inclusion in this directory is not an endorsement.